Scroll To Top
News

Fuzeon Receives Approval, Will Cost Almost $20,000 a Year

Fuzeon Receives Approval, Will Cost Almost $20,000 a Year

Coverx60_174

The Food and Drug Administration approved Fuzeon, Trimeris and Roche's HIV fusion inhibitor, on March 13, making the drug the first approved medication in the fusion inhibitor class. Fuzeon, also known as T-20, works by preventing HIV from being able to attach to and enter immune system cells. The drug, which must be injected, was designed primarily for HIV-positive people who have failed all other available treatments. Roche announced March 20 that the cost of the drug in the United States will be just under $20,000, making it the most expensive anti-HIV medication on the market. A complex manufacturing process will limit production of the drug to supply between 12,000 to 15,000 people by the end of the year. It will be available on a first-come, first-served basis.

Advocate Channel - The Pride StoreOut / Advocate Magazine - Fellow Travelers & Jamie Lee Curtis

From our Sponsors

Most Popular

Latest Stories

HIV Plus Editors

Editor

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.